FDA approves Gazyva for idiopathic nephrotic syndrome patients 2 years and older

The FDA said Gazyva (obinutuzumab) is approved to reduce relapse risk in pediatric and adult patients 2 years and older. It carries boxed warnings for hepatitis B reactivation and progressive multifocal leukoencephalopathy.